- Home
- ARMP vs TRBG Comparison
ARMP vs TRBG Comparison
Compare ARMP & TRBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARMP | TRBG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 186.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARMP | TRBG |
|---|---|---|
| Price | $5.38 | $4.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 82.8K | ★ 195.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $4.16 |
| 52 Week High | $14.98 | $5.84 |
Technical Indicators
Market Signals| Indicator | ARMP | TRBG |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | N/A |
| Support Level | $5.12 | N/A |
| Resistance Level | $5.63 | N/A |
| Average True Range (ATR) | 0.44 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 48.63 | 0.00 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.